Table 2 Comparison of ICHOM outcome measures for macular degeneration and reported measures in study hospitals
From: Mapping standard ophthalmic outcome sets to metrics currently reported in eight eye hospitals
Item | Propose ICHOM Measure | Reported measure in study hospitals | Number of hospitals reporting | Target | Reported value | |
|---|---|---|---|---|---|---|
Visual functioning and vison-related quality of life | Distance visual acuity | Distance visual acuity (best of uncorrected, corrected, or pinhole) in the affected eye. | Gain VA (15 ETDRS letters) after injections for macular degeneration | 1/8 | > 20% | 20.7% |
Visual stability (loss < 15 ETDRS letters) after injections for macular degeneration | 1/8 | > 80% | 90.25% | |||
Mobility and independence | Impact of vision impairment questionnaire | NA | 0/8 | None | NA | |
Emotional well-being | Impact of vision impairment questionnaire | NA | 0/8 | None | NA | |
Reading and accessing information | Impact of vision impairment questionnaire | NA | 0/8 | None | NA | |
Disutility of care | Number of treatments | Documentation of individual treatments received for macular degeneration | Appointment access and check in (% best response) | 1/8 | None | ≈ 63% |
Clinic wait times and comfort (% best response) | 1/8 | None | ≈ 45% | |||
Complications of treatment | Endophthalmitis: severe intraocular inflammation within 3 months of last intraocular treatment | Endophthalmitis after anti-VEGF intravitreal injections | 5/8 | None or 0.2–1.9%a 0.05% (MARINA) | 0–0.18% | |
Disease control | Presence of fluid, edema, or hemorrhage | Presence of intraretinal or subretinal fluid or hemorrhage that is attributable to activity of the neovascular lesion | NA | 0/8 | None | NA |